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Arterial embolism with lower limb ischemia is a rare manifestation of paraneoplastic hypercoagulability in cancer patients. We
report a unique case of fatal thromboembolism involving both circulations associated with a poorly differentiated neuroendocrine
tumor of the lungwith rapid progress despite high doses of unfractioned heparin and review the current literature on anticoagulative
regimen in tumour patients.
1. Introduction
Limb ischemia due to arterial embolism in cancer patients
has been reported for phaeochromocytoma, malignant
melanoma, angiosarcoma, or cardiac tumour patients [1–
3]. Single cases have also been linked to pancreatic adeno-
carcinoma or carotid body paraganglioma [4, 5]. Tumour
associated venous thrombosis with pulmonary embolism on
the other hand is much more common. Compared to a
normal population, cancer patients bear a thirty times greater
risk of deep vein thrombosis [6].
Vascular tumour invasion, metastatic spread, and frag-
mentation of cardiac masses need to be distinguished
from paraneoplastic effects like catecholamine associated
vasospasm, protein precipitation, and hypercoagulability [7].
The latter is of largely unknown origin and is responsible
for about 10% of cancer-related thromboembolisms [8, 9].
Additionally, catecholamine independent arterial vasospasm
leading to limb ischemia has been recently reported in a
patient with well-differentiated pulmonary neuroendocrine
carcinoma [10].
Embolism suggestive of Trousseau syndrome may occur
as initial symptom resulting in tumour diagnosis, as compli-
cation alongside disease progression or may be triggered by
specific chemotherapy agents [11, 12]. Thromboembolism is
the second leading cause of death in cancer patients [13].
Here we report the unique case of a patient diag-
nosed with a multilocular metastasized neuroendocrine
tumour (NET) of the lung suffering from progressive arterial
embolisms in both circulations leading to bilateral lower limb
ischemia, pulmonary embolism, stroke, and finally death five
weeks after the initial bout of chemotherapy despite high
doses of unfractioned heparin.
2. Case Report
A 58-year-old Caucasian male was admitted to the Oncology
Department with polyuria and weight loss of seven kilos in
the last two weeks. Risk factors were arterial hypertension
and cigarette smoking. Syndrome of inappropriate antidi-
uretic hormone secretion (SIADH) with hyponatremia was
noticed and tumour search detected metastatic liver disease
and enlarged hilar lymph nodes. Blood analysis revealed
elevated levels for neuron-specific enolase (NSE), carci-
noembryonic antigen (CEA), cytokeratin-fragment (Cyfra),
and liver biopsy specified metastases of a small cellular,
poorly differentiated neuroendocrine tumour (NET). Further
2 Case Reports in Vascular Medicine
staging via FDG PET disclosed the primary tumour near
the left lung hilus with positive mediastinal and hilar lymph
nodes, diffuse osseous filiarisation, and a sole metastasis in
the right adrenal gland. Oncology board consensus decision
was made for palliative chemotherapy with cisplatin and
etoposid (80mg/sqm, 120mg/sqm, resp.) as common for
dedifferentiated NET.
Two weeks after the initial bout of chemotherapy the
patient presented in the Surgical Department with incom-
plete ischemia of the left lower limb. Immediate interven-
tional recanalization failed and open embolectomy of the
tibiofibular trunk with consecutive venous patch plasty was
performed. Histological examination of the embolus showed
no malignancy. Three days later reischemia of the same leg
occurred and the operative procedure was repeated. Search
for embolic origin by CT-scan disclosed clinically inapparent
pulmonary embolism in three lobes. Mural thrombus of
the infrarenal aorta with perifocal aortic wall calcifications
appeared identical to the initial staging CT (Figure 1). All
tumourmanifestations showed downsizing in response to the
previous systemic chemotherapy. High doses of unfractioned
heparins (up to 40.000 IE/d) were administered for anticoag-
ulation. Aspirin was given for platelet inhibition. Activated
partial thromboplastin time presented sufficiently prolonged
with normal levels of antithrombin III when symptoms
began.
Again four days later, transfemoral and pedal embolec-
tomy with multilocular patch plasties of all native crural
arteries as ultima ratio due to complete ischemia had to
be performed. Decision was made for major amputation
as symptoms recurred again two days later. After clinical
signs of ischemia of the contralateral limb and respiratory
impairment, all parties agreed upon the best supportive care
concept. The patient died three days later after an additional
stroke with left-sided hemiplegia. Autopsy revealed right-
sided heart failure due to new severe pulmonary embolism
as cause of death, as well as heavy thrombotic alterations of
all major arterial vessels (Figure 2).
3. Discussion
To our best knowledge this is the first case with fulminant
arterial embolisms involving the lung, brain, and both legs
within a two-week period despite high doses of unfrac-
tioned heparins as paraneoplastic symptoms of amultilocular
metastasized NET.
Initially, calcifications of the infrarenal aorta with intra-
luminal thrombus were suggested as origin of embolism and
protective stenting was discussed but not conducted due to
the rapid chain of events (Figures 1 and 2). Retrospectively
with additional embolism upstream, the abdominal aorta as
well as the lesser circulation would have been oblivious.
Conclusively, paraneoplastic or chemotherapy-triggered
hypercoagulability remains as possible explanations for gen-
eralized thromboembolic disease.
Paraneoplastic syndromes occur in about 10% of malig-
nant diseases and are defined as symptom complexes that
cannot be readily explained by either the local or distant
Figure 1: Abdominal CT-scan showing diffuse calcifications of the
infrarenal aorta and aortic bifurcation (#) as well as mild ectasia
(3 cm). Note the diffuse hepatic metastatic disease (x).
(a) (b)
Figure 2: Pictures taken after autopsy of the right carotid bifurcation
(a) with occluding thrombus in both branches. Please note the
typical lines of Zahn at the arterial thrombus as a sign of continuing
thrombus formation (arrow). The infrarenal aorta (b) shows multi-
ple ulcerated arteriosclerotic plaques with mural thrombus luminal
occlusion of the left common iliac artery (arrow).
spread of cancer cells or specific secretory products [14].
Constitutive overexpression of procoagulative tissue factor
and phosphatidylserine could be shown to be responsible
for arterial and venous embolism in human malignant
melanoma and phaeochromocytoma cell lines [12, 15]. Onco-
gene activation and tumour suppressor gene inactivation
such as PTEN,MET, or p53 are thought to upregulate clotting
pathways [16]. Activated endothelium in melanoma patients
seems to additionally promote platelet activation [17]. Neural
crest cell origin of NET might be a possible explanation
for the involvement of many different pathways resulting in
coagulation disorders [18].
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Cisplatin, as part of the chemotherapeutic regimen
among other substances such as thalidomide, is known to
trigger thromboembolism in cancer patients with different
nonrelated tumour entities [19–21]. The DNA-crosslinking
drug is thought to provoke endothelial dysfunction and
platelet activation by phosphatidylserine expression [22]. On
the other hand, cisplatin based chemotherapy could be shown
to improve symptoms of disseminated intravascular coagula-
tion in a patient withmetastasized gastric adenocarcinoma as
treatment of the underlying malignancy [23].
Some authors have reported secondary heparin-induced
thrombocytopenia (HIT) of type II in cancer patients sug-
gesting a higher incidence due to bone marrow infiltration
[24, 25]. HIT II antibody diagnostic was negative and HIT-
related white-clot syndrome was not noticed at autopsy [26].
However, platelet count dropped to <50 × 109/litre as the
patient worsened rapidly.
In terms of which anticoagulant drug to administer
in paraneoplastic embolism, low-molecular-weight heparin
(LMWH) seems to be superior compared to unfractioned
heparin (UFH) and vitamin K antagonists. This assump-
tion is mainly supported by studies with patients suffering
from deep vein thrombosis [27, 28]. Regarding arterial
embolism no substantial clinical studies or guidelines have
been published until now. Some authors suggest UFH or
LMWH in combination with the direct thrombin inhibitor
fondaparinux [6, 29]. In this context, UFH is known to affect
more different sites in the coagulation cascade as LMWH
[30]. The role of platelet inhibition is unclear.
4. Conclusion
Lower limb ischemia in tumour patients is a severe paraneo-
plastic complication and might be the first clinical sign in a
fast chain of overwhelming thromboembolic events. Tum-
ours of neural crest origin seem to bear a high risk of hyperco-
agulation. Adequate surgical intervention and sufficient anti-
coagulation are the only treatment options and may be still
too late. Further substantial research on anticoagulative treat-
ment in tumour patients suffering from severe thromboem-
bolic complications is needed.
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